8:00 am
Coffee Room Opens

8:50 am
Chair’s Opening Remarks

Pivotal Clinical Data

9:00 am Breakfast C-Level Panel Discussion: Overcoming Challenges in the Field & Current Thoughts on Progress

  • Stephen Glover Co-Founder, Chairman & Chief Executive Officer, ZyVersa
  • Adam Keeney President & Chief Executive Officer, NodThera
  • Anil Goyal Chief Executive Officer & Board Director, IMMvention Therapeutix


  • Thinking outside the box when it comes to disease indications to identify and prioritize for inflammasome therapeutic success
  • Balancing commercial considerations of drug development with unmet need across diseases
  • How crucial is it to demonstrate differentiation from standards of care or other inflammasome inhibitors?
  • Should you plan for comparative data with standards of care in preclinical models before selecting indications and comparing across modalities?
  • Exploring the deals in the space: How to raise capital, attract investors and large pharma interest
  • Thoughts on evidence that activation of more than one type of NLR act is pathogenic – are people going to take different directions to drug development now?

9:30 am A Phase 1b Study to Test the Safety, Pharmacokinetics, & Pharmacodynamics of a Novel NLRP3 Inflammasome Inhibitor in Early- Stage Parkinson’s Disease


  • Exploring the drug discovery process: target identification and validation, efficacy, pathway understanding and biomarkers
  • Discussing biomarker and patient status
  • Reviewing latest data and future directions

10:00 am Discovery, Characterization, & Advancement, of Novel Chemotypes of Potent & Selective Brain Penetrant & Peripherally Restricted NLRP3 Inhibitors


Hear about the first study of Selnoflast in participants with early idiopathic PD; characterization of a new compound targeting NLRP3 inflammasome and innovative Ph1b design to test safety, pharmacokinetics and pharmacodynamics

10:30 am
Morning Refreshments & Poster Session


This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings

Inflammasome Crosstalk with Other Systems
Chair: Adam Schwaid, Associate Principal Scientist, Merck & Co., Inc.

11:30 am Recent Insights Into NLRP1 & CARD8 Inflammasome Activation


  • Review the impact of reductive stress on inflammasome activation
  • Discuss the impact of XP peptide accumulation on inflammasome activation
  • Find potential links between reductive stress and XP peptides

12:00 pm Dietary Fiber-Derived Gut Microbiota Metabolites as a Modulator of NLRP3 Inflammasome Function

  • Vishal Singh Assistant Professor - Nutritional Sciences & Microbiome, Penn State


  • What are the genomic associations between individual patient risks and inflammasome biology?
  • Are there any emerging immune signatures that can be used to identify patient responders?

Inflammasome Pathway Targets Downstream of Inflammasome Activation

12:30 pm Novel ASC Antibodies Reduce Inflammasome Activation And Propagation Of Inflammation In Vitro & In Vivo


Session details to be announced

Exploring Novel Targets & The Push to the Clinic

11:30 am ADS032: a Novel Dual NLRP1 & NLRP3 Inhibitor to Target Inflammasome Inflammation


  • Learn about ADS032, a novel dual inflammasome inhibitor
  • Discover how ADS032 reduces inflammation both in vitro and in vivo
  • Evaluate how ADS032 reduces the inflammatory burden during inflammasome-related disease

12:00 pm First in Human Dosing of HT-6184, a Novel Allosteric NEK7 Inhibitor Targeting NLRP3 Assembly & Function

  • David Bearss Chief Executive Officer & President, Halia Therapeutics


  • Explore how targeting the ability of Nek7 to bind to NLRP3 blocks and activation and promotes disassembly of the NLRP3 Inflammasome
  • Review how HT-6184 potently blocks NLRP3 activity and function
  • Evaluate data on the PK and PD of HT-6184 in the firstin- human trial that will be presented

Inflammasomes in Cancer: Translational Efforts

12:30 pm An Update on the Monogenic Inflammasomopathies with a Focus on CAPS

  • Hal Hoffman Professor of Pediatrics & Medicine & Chief of the Division of Allergy, Immunology and Rheumatology in the Department of Pediatrics, UC San Diego/Rady Children’s Hospital


  • Exploring the clear clinical endpoints to mark therapeutic success
  • Delving into what biomarkers to use for patient inclusion criteria

1:00 pm
Networking Lunch

2:00 pm Mechanism of Action of IC 100, A Humanized Monoclonal Antibody Against ASC


  • Exploring the drug discovery process: target identification and validation, efficacy, pathway understanding and biomarkers
  • Latest data & future directions

2:30 pm Novel Antibodies Targeting the Inflammasome to Treat Neurodegeneration


  • Discuss how the inflammasome is a promising target in neurodegenerative diseases
  • Learn how abylon has identified novel monoclonal antibodies that hold promise for the treatment of neurodegeneration

2:00 pm Inflammasomes’ Role in Mechanisms of Tumor Resistance


*Speaker TBC

  • Explore a translational update on this space
  • Learn how to target inflammasomes in cancer
  • Does inflammasome activation come up in mechanisms of tumor resistance?
  • Understanding the impact of perturbing inflammation and inflammasome activity on immune cells in the tumor microenvironment

2:30 pm Inflammasomes and the Control of Anti-Tumor Immunity

  • Jonathan Kagan Marian R. Neutra, PhD Professor of Pediatrics, Harvard Medical School


  • Exploring any actionable mutations/established cancer biomarkers and any relation with inflammasome activity
  • How can we translate this knowledge into therapeutic combination regimens for patients?

3:00 pm
Afternoon Refreshments

Linking Specific Inflammasomes to Human Disease

3:30 pm Panel Discussion: How to Characterise Rational Biomarkers/Endpoints?

  • Karen Cashmere Chief Commercial Officer, ZyVersa
  • Kate Fitzgerald Professor & Vice Chair, Department of Medicine Division of Innate Immunity, University of Massachusetts Chan Medical School
  • Juan Pablo de Rivero Vaccari Associate Professor of Neurological Surgery & The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
  • Dianne McKay Professor of Immunology & Microbiology, The Scripps Research Institute


  • Exploring biomarker selection – clinical presence of inflammation in the diseases
  • Utility in assessing disease progression and control of disease
  • What is a clinically meaningful benchmark of inflammasome inhibition?
  • What are the best tissue biomarkers of inflammasome inhibition?
  • What biomarkers and assays should be measured in a phase 1 or phase 2 trial to demonstrate inflammasome inhibition?
  • Overcoming the challenge of a lack of biomarkers to enable early intervention in disease
  • Validating assays in knockout models and testing assays in biological (plasma/serum) samples
  • Thoughts on future directions of this space and how companies can cover as many diseases as possible

4:30 pm
Chair’s Closing Remarks & End of Summit